SYNTHETICMR Aktie

 

June 13, 2025 The Board of Directors of SyntheticMR AB (publ) has appointed Lena Åredal as the company's new Chief Executive Officer. She will assume the position no later than December 15, 2025. Until then, Acting CEO Johanna Norén will continue in her interim role and thereafter return to her position as CFO. Lena Åredal currently serves as CEO of Perimed, a Swedish medtech company specializing in microcirculation diagnostics with global sales. During her tenure at Perimed, she has been responsible for the company's OEM partnerships, established a direct sales organization in the...

LINKÖPING, Sweden, June 3, 2025 /PRNewswire/ -- SyntheticMR AB (publ) is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology (AJNR), demonstrating the diagnostic equivalence—and potential advantages—of SyMRI® using the......

The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on May 20, 2025, whereby the meeting resolved in accordance with the Nomination Committee and Board's proposed resolutions. The full resolutions are stated in the notice of the meeting. The following resolutions were made at the AGM: The AGM resolved to approve the Board's proposal that no dividend will be paid. The remaining capitalized funds of SEK 71,928,452 including the share premium reserve and retained earnings, are transferred in new accounts. The AGM resolved to grant the Board of directors and CEO...

The shareholders of SyntheticMR AB (publ), corporate Reg. No. 556723-8877, are hereby invited to attend the annual general meeting on Tuesday 20 May 2025, at 18:00 CET at the company's premises on Storgatan 11 in Linköping. Right to attend the general meeting Shareholders who wish to attend the general meeting must: · be registered as a shareholder in share register maintained by Euroclear Sweden AB on the record date, Monday 12 May 2025, and · no later than Wednesday 14 May 2025 at 16:00 CET notify the company of its and any assistants' (no more than two) intention to attend...

SyntheticMR AB (publ) hereby announces that the Group´s annual report for 2024 has been published. The annual report is also available on SyntheticMRs website www.syntheticmr.com The english annual report is a translation of the swedish version. The swedish annual report shall prevail in case of conflict....

SyntheticMR, global leader in quantitative imaging software, is pleased to announce that its cutting-edge SyMRI 15 (3D) solution has received regulatory clearance in Japan. This approval permits distribution of SyMRI 3D across Japan and will enhance SyntheticMR's strong market position and benefit healthcare providers in the region. SyMRI 3D is designed to improve diagnostic outcomes by providing high-resolution, rich quantitative data in 3D, including quantitative values, accurate segmentation, and adjustable contrasts.  A prospective, multi-center, multi-reader clinical investigation to...

January 21, 2025 Vedran Beglerbegovic has today informed the Board of Directors that he is resigning from the position as CEO of SyntheticMR due to medical reasons. The board has appointed CFO Johanna Norén as Acting CEO. The board will begin a recruitment process for a new CEO. For more information, please contact: Staffan Persson, Chairman, tel. +46 70-321 00 98 Johanna Norén, Acting CEO, tel. +46 70 619 21 00...

January 17, 2025 Ulrik Harrysson has today informed the Board of Directors of his resignation as CEO with immediate effect. The Board of Directors of SyntheticMR has appointed Vedran Beglerbegovic as new CEO. Vedran has been acting CEO since December 4 2024 while Ulrik has been on medical leave. Vedran has been part of SyntheticMR since 2021, his latest role was the Chief Operating Officer. He comes with experience of many years within product management and commercialization within MedTech. He has been studying  Applied Physics & Electronical Engineering at Linköping University....

16 january 2025 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. SyntheticMR AB (publ) ("SyntheticMR" or the "Company") announces the final outcome of the Company's rights issue of up to 17 866 405 shares, which the board of directors of the Company resolved on 28...

14 January 2025 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. SyntheticMR AB (publ) ("SyntheticMR" or the "Company") announces the preliminary outcome of the Company's rights issue of up to 17 866 405 shares, which the board of directors of the Company resolved on...

SyntheticMR AB ("SyntheticMR" or the "Company") has today, the 2[nd] of January 2025, acquired all shares in Finnish Combinostics Oy ("Combinostics").The purchase price amounts to a total of EUR 4.3 million (corresponding to approximately SEK 49.6 million[1] ), of which approximately EUR 3.93 million (corresponding to approximately SEK 45.3 million) is paid in cash, and the remaining part of approximately EUR 0.37 million (corresponding to approximately SEK 4.3 million) through a promissory note set off against convertibles. The conversion price for the convertibles will be SEK 12 and the...

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. SyntheticMR AB (publ) ("SyntheticMR" or the "Company") publishes disclosure document relating to the rights issue of shares of approximately SEK 65 million before deduction of issue costs, which was resolved by the board...

Das Instrument 9480 SE0015987946 SYNTHETICMR AB AK EQUITY wird ex Kapitalmassnahme gehandelt am 18.12.2024 The instrument 9480 SE0015987946 SYNTHETICMR AB AK EQUITY is traded ex capital adjustment on 18.12.2024...

The extra general meeting of SyntheticMR AB (publ) ("SyntheticMR" or the "Company") was held today on 17 December 2024 and the following resolutions were passed by the meeting. Approval of the board's resolution on a rights issue of shares The extra general meeting resolved to approve the board of directors' resolution on 28 November 2024 on a rights issue of a maximum of 17,866,405 shares. The total increase of the Company's share capital amounts to a maximum of SEK 396,634.191. The subscription price to be paid for each share shall be SEK 3.65, in total SEK 65,212,378.25 if all...

Das Instrument 9480 SE0015987946 SYNTHETICMR AB AK EQUITY wird cum Kapitalmassnahme gehandelt am 17.12.2024 und ex Kapitalmassnahme am 18.12.2024 The instrument 9480 SE0015987946 SYNTHETICMR AB AK EQUITY is traded cum capital adjustment on 17.12.2024 and ex capital adjustment on 18.12.2024...

SyntheticMR, leader in quantitative imaging software, is pleased to announce that its SyMRI 15 solution has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) on diagnostic image replacement of conventional images. SyMRI 15 offers an innovative approach to MRI, transforming traditional imaging methodologies with its advanced synthetic imaging technology. Clinically validated through extensive multi-center studies across leading institutions in the United States, SyMRI 15 has proven its capability to enhance imaging workflows by replacing conventional 3D imaging...

The board of SyntheticMR AB (publ) has today decided to appoint Vedran Beglerbegovic as Acting CEO with immediate effect, due to the current CEO, Ulrik Harrysson, being on sick leave indefinitely. Vedran Beglerbegovic, who currently holds the position of COO within the company, will lead the operations during Ulrik Harrysson's absence. Vedran Beglerbegovic has been part of SyntheticMR since 2021. For further information, please contact: Vedran Beglerbegovic, Acting CEO                   Phone: 079-0772720 E-mail: vedran.beglerbegovic@syntheticmr.com Staffan Persson, Chairman...

The shareholders of SyntheticMR AB (publ), reg. no. 556723-8877, (the "Company") are hereby invited to the extra general meeting on Tuesday 17 December 2024 at 13:00 CET at the Company's premises on Storgatan 11 in Linköping. Right to attend the general meeting Shareholders who wish to attend the general meeting must: · be registered in the share register maintained by Euroclear Sweden AB on the record date, Monday 9 December 2024; and · no later than Wednesday 11 December 2024 notify the Company of their participation and any assistants by: i.    post to SyntheticMR AB (publ),...

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. 28 November 2024, 23:05 CET The board of directors of SyntheticMR AB (publ) ("SyntheticMR" or the "Company") has today, subject to an approval by an extraordinary general meeting, resolved to carry out a new share...

28 November 2024, 22:55 CET SyntheticMR AB ("SyntheticMR" or the "Company") has signed an agreement to acquire Finnish Combinostics Oy ("Combinostics"), through the acquisition of all shares in Combinostics, a leading medical technology and software solutions company focusing on cloud-based and AI-driven platforms. The acquisition is subject to approval by an Extraordinary General Meeting. Notice of the EGM will be published through a separate press release. The purchase price amounts to a total of EUR 4.3 million (corresponding to approximately SEK 49.6 million[1] ), of which...